Published online Mar 25, 2022. doi: 10.5501/wjv.v11.i2.111
Peer-review started: September 29, 2021
First decision: January 12, 2022
Revised: January 12, 2022
Accepted: March 15, 2022
Article in press: March 15, 2022
Published online: March 25, 2022
Processing time: 173 Days and 15.3 Hours
In a recent meta-analysis the prevalence of coronavirus disease 2019 (COVID-19)-associated hyperglycemia was 25%, and that of COVID-19-associated new-onset diabetes was 19%. An association between hyperglycemia or new-onset diabetes and COVID-19 has been suggested. In a recent relevant study of critically and non-critically ill patients with COVID-19, we found that indeed beta-cell function was compromised in critically ill patients with COVID-19 and that these patients showed a high glycemic gap. Nevertheless, one quarter of critically ill patients with no history of diabetes have stress hyperglycemia, a finding which could obscure the prevalence of hyperglycemia or new-onset diabetes that could be attributed to COVID-19 per se.
Core Tip: An association between hyperglycemia or new-onset diabetes and coronavirus disease 2019 (COVID-19) has been suggested. Nevertheless, one quarter of critically ill patients with no history of diabetes have stress hyperglycemia, a finding which could obscure the prevalence of hyperglycemia or new-onset diabetes that could be attributed to COVID-19 per se.